Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Rating of “Buy” from Analysts
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $20.78.
INO has been the topic of a number of recent research reports. Aegis restated a “buy” rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Maxim Group lifted their price objective on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $11.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, April 25th. Finally, Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 17th.
Shares of Inovio Pharmaceuticals (INO) traded up 2.670% during trading on Friday, hitting $5.575. 1,050,511 shares of the company were exchanged. Inovio Pharmaceuticals has a 12 month low of $5.32 and a 12 month high of $9.95. The company’s 50-day moving average price is $7.16 and its 200 day moving average price is $6.84. The stock’s market cap is $416.05 million.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. During the same period last year, the firm posted ($0.11) EPS. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. On average, equities analysts predict that Inovio Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.
In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the sale, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.60% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $392,000. Schwab Charles Investment Management Inc. raised its position in shares of Inovio Pharmaceuticals by 9.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 334,017 shares of the biopharmaceutical company’s stock worth $2,619,000 after buying an additional 28,173 shares during the period. Candriam Luxembourg S.C.A. bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $1,411,000. Private Capital Advisors Inc. bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $274,000. Finally, Credit Suisse AG raised its position in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares during the period. 22.92% of the stock is currently owned by institutional investors and hedge funds.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.